MarginsXMarginsX
Home › Markets › Health Care › ARWR

Arrowhead Pharmaceuticals Inc. (ARWR)

ARWR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$44.21
-7.47% on the day
Market cap
$6.2B
Mid cap
Revenue · 2026
$450.8M
-45.6% on 2025
Net income · 2026
-$724.2M
-160.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-09-30, https://www.sec.gov/Archives/edgar/data/879407/000087940726000078/0000879407-26-000078-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-09-30.

Profile

FieldValue
TickerARWR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000879407
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2026

LineValue
Revenue$450.8M
Net income-$724.2M
Operating income-$707.2M
Net margin-160.6%
Operating margin-156.9%
Revenue growth-45.6%
Cash$62.7M
Total assets$1.7B
P/E (computed)Net income was not positive
P/S (computed)13.9×

Warning signs

Cash runway
2.8 months
$62.7M cash at September 30, 2026
Share count, 1 year
+4.1%
2025-11-19 to 2026-11-05 · +31.6% over 3 years
Going-concern doubt
No
10-K filed November 12, 2026
Insider net buying, 12 months
-$38.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-K 2026-11-12
Cash and burn$62.7M cash; operating cash flow -$68.0M a quarter.Report 2026-09-30
Shares outstanding141,368,004 (2026-11-05); 135,809,558 a year earlier; 107,432,210 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-01-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United StatesPCAOB Form AP 2025-12-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $38.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-09-30
$37.8M-$428.0M-$192.4M$62.7M$683.5M$450.8M10-K 2026-11-12
Q3 2026
2026-06-30
$75.3M-$194.3M-$177.5M$54.8M$682.7M$669.5M10-Q 2026-08-04
Q2 2026
2026-03-31
$73.7M-$132.7M$84.4M$188.5M$681.9M$622.0M10-Q 2026-05-07
Q1 2026
2025-12-31
$264.0M$30.8M$13.5M$201.6MNo debt tags$1.1B10-Q 2026-02-05
Q4 2025
2025-09-30
$256.5M-$23.8M$20.5M$226.5M$0$829.4M10-K 2026-11-12
Q3 2025
2025-06-30
$27.8M-$175.2M-$154.7M$129.8MNo debt tags$573.0M10-Q 2026-08-04
Q2 2025
2025-03-31
$542.7M$370.4M$460.1M$185.7MNo debt tags$545.2M10-Q 2026-05-07
Q1 2025
2024-12-31
$2.5M-$173.1M-$146.3M$53.9MNo debt tags$2.5M10-Q 2026-02-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-01-09
Latest annual report10-K2026-11-12
Latest quarterly / interim10-Q2026-08-04
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-01-27

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-17.8%
1 month-17.8%
3 months-44.2%
Year to date-28.0%
1 year+16.1%
From 52-week high-46.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LGNDLigand Pharmaceuticals Incorporated$301.71-2.29%$6.0B
GRFSGrifols S.A.$8.73+0.46%$6.0B
SUPNSupernus Inc.$28.83-2.99%$6.0B
MIRMMirum Pharmaceuticals Inc.$91.58-2.56%$6.0B
BLTEBelite Bio Inc$162.56-1.09%$6.5B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
MANEVeradermics Incorporated$128.05-1.24%$5.4B
ABVXAbivax SA$83.61-4.53%$7.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier